{
    "organizations": [],
    "uuid": "28d282fb2b95f8becbbd4cc31d332c6ef77cedda",
    "author": "",
    "url": "https://www.reuters.com/article/brief-hikma-gets-us-fda-response-on-anda/brief-hikma-gets-u-s-fda-response-on-anda-for-generic-version-of-gsks-advair-diskus-idUSFWN1QT086",
    "ord_in_thread": 0,
    "title": "BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 7:39 AM / Updated 20 minutes ago BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus Reuters Staff March 12 (Reuters) - Hikma Pharmaceuticals Plc: * UPDATE STATUS ON ANDA FOR GENERIC ADVAIR DISKUS * HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE’S ADVAIR DISKUS * REMAINED OUTSTANDING ISSUE REGARDING CLINICAL ENDPOINT STUDY, IN RESPONSE, DECIDED TO ENGAGE IN FDA’S DISPUTE RESOLUTION PROCESS​ * HIKMA HAS ALREADY FINALISED PLANNING OF A NEW CLINICAL STUDY AND EXPECTS TO START PATIENT ENROLMENT IN COMING WEEKS * ‍HIKMA ANTICIPATES BEING ABLE TO SUBMIT A RESPONSE TO FDA WITH NEW CLINICAL DATA AS EARLY AS POSSIBLE IN 2019​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T09:37:00.000+02:00",
    "crawled": "2018-03-12T10:08:22.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "get",
        "fda",
        "response",
        "anda",
        "generic",
        "version",
        "gsk",
        "advair",
        "diskus",
        "reuters",
        "staff",
        "march",
        "reuters",
        "hikma",
        "pharmaceutical",
        "plc",
        "update",
        "status",
        "anda",
        "generic",
        "advair",
        "diskus",
        "received",
        "response",
        "fda",
        "relation",
        "anda",
        "generic",
        "version",
        "glaxosmithkline",
        "advair",
        "diskus",
        "remained",
        "outstanding",
        "issue",
        "regarding",
        "clinical",
        "endpoint",
        "study",
        "response",
        "decided",
        "engage",
        "fda",
        "dispute",
        "resolution",
        "hikma",
        "already",
        "finalised",
        "planning",
        "new",
        "clinical",
        "study",
        "expects",
        "start",
        "patient",
        "enrolment",
        "coming",
        "week",
        "anticipates",
        "able",
        "submit",
        "response",
        "fda",
        "new",
        "clinical",
        "data",
        "early",
        "possible",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}